NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHGRI E-034-2019-0-MX-05 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA MX National Stage MX/a/2021/001062 Abandoned
NHGRI E-034-2019-0-KR-15 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency KR National Stage 10-2021-7007207 Abandoned
NHGRI E-034-2019-0-SA-10 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency SA National Stage 521421222 Abandoned
NHGRI E-034-2019-0-AU-04 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA AU National Stage 2018436152 Abandoned
NHGRI E-034-2019-0-BR-08 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency BR National Stage BR112021002332-1 Abandoned
NHGRI E-034-2019-0-IL-06 Targeted Integration Into The Albumin (Alb) Locus As A Treatment For Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MUT) Deficiency IL National Stage 1984-06-28 Abandoned
NHGRI E-034-2019-0-CA-11 NON-DISRUPTIVE GENE THERAPY FOR THE TREATMENT OF MMA CA National Stage 3109114 Pending
NCI E-269-2010-0-US-13 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE US CON 16/173,701 10864252 Issued PDF
NIAID E-139-2006-0-US-65 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS US DIV 16/173,217 10724007 Issued PDF
NCI E-190-2014-0-JP-13 VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF
TUMORS 		JP DIV 2018-202650 Issued
NCI E-229-2017-0-PCT-02 TREATING OR PREVENTING ADVERSE LIVER CONDITIONS PCT PCT PCT/US2018/057946 Expired
NIDCR E-184-2017-0-PCT-02 JACKETED CATHETER PROBES AND METHODS OF USE FOR INFUSION PCT PCT PCT/US2018/057744 Expired
NLM E-107-2010-2-US-23 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/172,369 Abandoned
NIDCR E-184-2017-0-EP-03 JACKETED CATHETER PROBES AND METHODS OF USE FOR INFUSION EP National Stage 18800450.1 Abandoned
NIAID E-187-2018-0-US-01 A HIGH-YIELD PERFUSION-BASED TRANSIENT GENE EXPRESSION BIOPROCESS US 62/751,204 Abandoned
NCATS E-051-2020-0-US-01 Crystal Forms Of An ALK2 Inhibitor US 62/751,255 Abandoned
NHGRI E-044-2013-1-NZ-14 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA NZ National Stage 747685 Issued
NHGRI E-044-2013-1-US-16 Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human Lamin A (LMNA) US National Stage 16/096,524 10822608 Issued PDF
NCATS E-116-2016-0-EP-06 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE EP National Stage 17716350.8 Pending
NCI E-153-2016-0-US-06 ANTI-KK-LC-1 T CELL RECEPTORS US National Stage 16/096,118 11352410 Issued PDF
NLM E-107-2010-2-US-22 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/169,801 10465234 Issued PDF
NCI E-166-2018-0-US-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US 62/749,750 Abandoned
NINDS E-146-2016-1-EP-02 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP National Stage 17733098.2 Issued
NINDS E-146-2016-1-BE-07 Selective D3 Dopamine Receptor Agonists and Methods of Their Use BE EP 17733098.2 Issued
NINDS E-146-2016-1-CH-09 Selective D3 Dopamine Receptor Agonists and Methods of Their Use CH EP 17733098.2 Issued
NINDS E-146-2016-1-GB-05 ESelective D3 Dopamine Receptor Agonists and Methods of Their Use GB EP 17733098.2 Issued
NINDS E-146-2016-1-IE-08 Selective D3 Dopamine Receptor Agonists and Methods of Their Use IE EP 17733098.2 Issued
NINDS E-146-2016-1-DE-04 Selective D3 Dopamine Receptor Agonists and Methods of Their Use DE EP 17733098.2 Issued
NINDS E-146-2016-1-FR-06 Selective D3 Dopamine Receptor Agonists and Methods of Their Use FR EP 17733098.2 Issued
NCI E-008-2018-0-CN-03 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY CN National Stage 201880069066.2 Issued
NCI E-008-2018-0-DE-08 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY DE EP 18808559.1 Issued
NCI E-008-2018-0-FR-09 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY FR EP 18808559.1 Issued
NCI E-008-2018-0-EP-04 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP National Stage 18808559.1 Issued
NCI E-008-2018-0-NL-11 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY NL EP 18808559.1 Issued
NCI E-008-2018-0-GB-10 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY GB EP 18808559.1 Issued
NCI E-008-2018-0-KR-06 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY KR National Stage 10-2020-7011517 Issued
NCI E-008-2018-0-JP-05 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY JP National Stage 2020-522670 Issued
NCI E-008-2018-0-PCT-02 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PCT PCT PCT/US2018/057128 Expired
NIAID E-216-2018-1-US-01 Multi-Specific Antibodies For HIV-1 And Their Utility US 62/749,510 Expired
NCI E-160-2018-0-US-01 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION US 62/748,905 Abandoned
NIDDK E-138-2017-0-IL-08 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS IL National Stage 262487 Issued
NCI E-131-2016-0-US-07 EVALUATON OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO US National Stage 16/094,965 11725248 Issued PDF
NCI E-153-2016-0-AU-03 ANTI-KK-LC-1 T CELL RECEPTORS AU National Stage 2017258745 Issued
NCI E-153-2016-0-BE-07 ANTI-KK-LC-1 T CELL RECEPTORS BE EP 17733120.4 Issued
NCI E-153-2016-0-IT-16 ANTI-KK-LC-1 T CELL RECEPTORS IT EP 17733120.4 Issued
NCI E-153-2016-0-IE-15 ANTI-KK-LC-1 T CELL RECEPTORS IE EP 17733120.4 Issued
NCI E-153-2016-0-GB-14 ANTI-KK-LC-1 T CELL RECEPTORS GB EP 17733120.4 Issued
NCI E-153-2016-0-CH-08 ANTI-KK-LC-1 T CELL RECEPTORS CH EP 17733120.4 Issued
NCI E-153-2016-0-NL-17 ANTI-KK-LC-1 T CELL RECEPTORS NL EP 17733120.4 Issued
NCI E-153-2016-0-DK-10 ANTI-KK-LC-1 T CELL RECEPTORS DK EP 17733120.4 Issued